Suppr超能文献

IB2期和II期宫颈癌患者在接受放化疗后,若影像学检查显示肿瘤局限于盆腔,腹主动脉旁受累情况及腹主动脉旁淋巴结清扫的意义。

Para-aortic involvement and interest of para-aortic lymphadenectomy after chemoradiation therapy in patients with stage IB2 and II cervical carcinoma radiologically confined to the pelvic cavity.

作者信息

Delpech Yann, Haie-Meder Christine, Rey Annie, Zafrani Yaelle, Uzan Catherine, Gouy Sebastien, Pautier Patricia, Lhommé Catherine, Duvillard Pierre, Castaigne Damienne, Morice Philippe

机构信息

Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France.

出版信息

Ann Surg Oncol. 2007 Nov;14(11):3223-31. doi: 10.1245/s10434-007-9526-1. Epub 2007 Aug 23.

Abstract

BACKGROUND

Pelvic radiation therapy with concomitant chemotherapy (PCRT) is the standard treatment of stage IB2/II cervical carcinoma. The impact of concomitant chemotherapy on positive para-aortic nodes (PA+), however, remains unknown. The aim of this study was twofold: to evaluate the rate of histological PA+ after PCRT and to determine the survival of patients with PA+.

METHODS

Patients fulfilling the following inclusion criteria were studied: (1) stage IB2/II cervical carcinoma, (2) histological subtype: squamous cell, adenocarcinoma or an adenosquamous tumor, (3) exclusion of patients with radiological PA+ (CT scan/MRI), (4) pelvic external radiation therapy of 45 Gy with concomitant chemotherapy (cisplatin 40 mg/m2/week) + utero-vaginal brachytherapy, and (5) completion surgery after the end of PCRT including at least a para-aortic lymphadenectomy.

RESULTS

Seventy-three patients (16 stage IB2, 57 stage II) treated between 1998 and 2004 fulfilled all the inclusion criteria. PA+ after PCRT were observed in 13 patients (18%) with a median of five (range, 2-22) positive nodes. Overall and disease-free survival at 24 months in patients with PA+ was 40% and 17%. Only two patients with PA+ are currently alive and in remission.

CONCLUSIONS

The rate of PA+ remains high after PCRT in patients treated for stage IB2/II cervical carcinoma. Furthermore, the survival rate of patients with PA+ is very low. These important results suggest that detection of PA + at the time of completion surgery (after PCRT) is not beneficial for improving survival.

摘要

背景

盆腔放疗联合化疗(PCRT)是IB2/II期宫颈癌的标准治疗方法。然而,同步化疗对阳性腹主动脉旁淋巴结(PA+)的影响尚不清楚。本研究的目的有两个:评估PCRT后组织学PA+的发生率,并确定PA+患者的生存率。

方法

研究符合以下纳入标准的患者:(1)IB2/II期宫颈癌;(2)组织学亚型:鳞状细胞癌、腺癌或腺鳞癌;(3)排除影像学显示PA+的患者(CT扫描/MRI);(4)盆腔外照射剂量为45 Gy,同步化疗(顺铂40 mg/m²/周)+子宫阴道近距离放疗;(5)PCRT结束后完成手术,至少包括腹主动脉旁淋巴结清扫术。

结果

1998年至2004年间治疗的73例患者(16例IB2期,57例II期)符合所有纳入标准。PCRT后13例患者(占18%)出现PA+,阳性淋巴结中位数为5个(范围为2-22个)。PA+患者24个月时的总生存率和无病生存率分别为40%和17%。目前只有2例PA+患者存活且病情缓解。

结论

对于接受IB2/II期宫颈癌治疗的患者,PCRT后PA+的发生率仍然很高。此外,PA+患者的生存率非常低。这些重要结果表明,在完成手术时(PCRT后)检测到PA+对提高生存率并无益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验